The global nanomedicine market was valued at $53 billion in 2009, and is forecast to increase at a compound annual growth rate (CAGR) of 13.5% to reach more than $100 billion in 2014.
Nanomedical products for cancer are one of the largets market segments, worth nearly $20 billion in 2009. This sector is expected to increase at a compound annual growth rate (CAGR) of 11% to reach $33 billion in 2014.
Nanomedicine for CNS indications is another major market sector, valued at nearly $11 billion in 2009 and expected to reach $18 billion by 2014, an 11.1% compound annual growth rate (CAGR).
STUDY GOALS AND OBJECTIVES
The aim of this report is to provide detailed market, technology and industry analyses to help readers quantify and qualify the market for prescription drug products incorporating nanotechnology features. Important trends are identified and sales forecasts by product categories and major country markets are provided through 2014; these are based on industry sources and considered assessment of the regulatory environment, healthcare policies, demographics, and other factors that directly affect the nanomedicine-related drug market. The wider economic environment is also taken into account.
The report examines strategies employed by companies specializing in nanomedicine to meet the challenges of this highly competitive market.
REASONS FOR DOING THE STUDY
Nanomedicine is transforming itself into an established market. Unlike some of the farther shores of nanotechnology, which are still largely experimental in nature, nanomedicine has already produced a healthy crop of significant products in which the nano dimension has made a significant contribution to product effectiveness. As the market grows towards maturity, it is timely to review the technology, see its practical applications so far, evaluate the participating companies, and look to the future of this marketplace.
This report is designed to satisfy the information needs of a wide variety of individuals involved in the pharmaceutical marketplace, including company senior management executives seeking to base their strategic decisions on the best available information on market forces and trends. However, it is also aimed at managers and executives in marketing, research, planning, and sales departments who need readable, comprehensive, and up-to-date background on the marketplace in which they are operating.
SCOPE OF REPORT
This report discusses the implications of technology and commercial trends in the context of the current size and growth of the pharmaceutical market, both in global terms and analyzed by the most important national markets. The important technologies supporting nanomedicine are reviewed, and the nature and structure of the nanomedicine industry is discussed with profiles of the leading 60-plus companies, including recent M&A activity. Five-year sales forecasts are provided for the national markets and the major therapeutic categories of products involved.
MARKET ANALYSES AND FORECASTS
Market figures are based on revenues at the manufacturer level and are projected at 2009-dollar value without attempting to predict the effect of inflation or deflation.
Therapeutic categories quantified and forecast include cancer, CNS diseases, infections, and cardiovascular. Country markets analyzed are the U.S., Japan, Germany, France, the UK, Italy, and Spain.
Both primary and secondary research methodologies were used when examining this market. Primary research includes interviews with leading individuals in nanomedicine companies and industry associations. Primary sources of published data include company annual reports, SEC filings, and government and industry publications. Secondary sources consist of literature searches, industry journals, and other commercial publications. Data for market estimates and forecasts are pooled from a range of sources, critically assessed by BCC.
Sources of information included marketing strategists, industry executives, government agencies and regulatory bodies, and surveys of physicians and pharmacists. Company annual reports and SEC filings, journal articles, and data from healthcare institutions were also mined, as well as publications of relevant trade associations.
Paul Evers has been involved in analyzing pharmaceutical and medical markets for 20 years. He is the author of previous reports on the nanomedicine marketplace as well as analyses of major therapeutic categories and the pharmaceutical regulatory environment.
BCC ONLINE SERVICES
BCC offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:
Examine BCC’s complete catalog of Market Research Reports and place direct orders
Subscribe to any of BCC’s many industry newsletters
Read announcements of recently published reports and newly launched newsletters
Register for BCC’s well-known conferences
Request additional information on any BCC product
Take advantage of special offers
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use.
BCC Research provides objective, unbiased measurement and assessment of market opportunities with detailed market research reports. Our experienced industry analysts assess growth opportunities, market sizing, technologies, applications, supply chains and companies with the singular goal of helping you make informed business decisions, free of noise and hype.
Thank you for your interest in BCC Research. You will be added to our mailing list.